Influence of geographical latitude on vitamin D status: cross-sectional results from the BiomarCaRE consortium

Viktor Oskarsson1*, Mats Eliasson1, Veikko Salomaa2, Jaakko Reinikainen2, Satu Männistö2, Luigi Palmieri3, Chiara Donfrancesco3, Susana Sans4, Simona Costanzo5, Giovanni de Gaetano5, Licia Iacoviello5,6, Giovanni Veronesi6, Marco M. Ferrario6, Teresa Padro7, Barbara Thorand8, Cornelia Huth8, Tanja Zeller9,10, Stefan Blankenberg9,10, Annie S. Anderson11, Hugh Tunstall-Pedoe12, Kari Kuulasmaa2, Stefan Söderberg1 and on behalf of the BiomarCaRE investigators

1Department of Public Health and Clinical Medicine, Umeå University, Umeå 90187, Sweden
2Department of Public Health Solutions, Finnish Institute for Health and Welfare, Helsinki, Finland
3Department of Cardiovascular, Endocrine-Metabolic Diseases and Aging, Istituto Superiore di Sanità-ISS, Rome, Italy
4Catalan Department of Health, Barcelona, Spain
5Department of Epidemiology and Prevention, IRCCS Neuromed, Pozzilli, Italy
6Department of Medicine and Surgery, University of Insubria, Varese, Italy
7Cardiovascular-Program ICCC, Research Institute Hospital Santa Creu i Sant Pau, IIB-Sant Pau, Barcelona, Spain
8Institute of Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuberberg, Germany
9University Heart and Vascular Center Hamburg, Medical University Hamburg-Eppendorf, Hamburg, Germany
10German Center for Cardiovascular Research, Partner Site Hamburg/Lübeck/Kiel, Hamburg, Germany
11Centre for Public Health Nutrition Research, University of Dundee, Dundee, Scotland
12Institute of Cardiovascular Research, University of Dundee, Dundee, Scotland

(Submitted 9 March 2021 – Final revision received 29 October 2021 – Accepted 14 December 2021)

Abstract

Even though sunlight is viewed as the most important determinant of 25-hydroxyvitamin D (25(OH)D) status, several European studies have observed higher 25(OH)D concentrations among north-Europeans than south-Europeans. We studied the association between geographical latitude (derived from ecological data) and 25(OH)D status in six European countries using harmonised immunoassay data from 81 084 participants in the Biomarkers for Cardiovascular Risk Assessment in Europe (BiomarCaRE) project (male sex 48.9%; median age 50.8 years; examination period 1984–2014). Quantile regression models, adjusted for age, sex, decade and calendar week of sampling and time from sampling to analysis, were used for between-country comparisons. Up until the median percentile, the ordering of countries by 25(OH)D status (from highest to lowest) was as follows: Sweden (at 65.6–63.8°N), Germany (at 48.4°N), Finland (at 65.0–60.2°N), Italy (at 45.6–41.5°N), Scotland (at 58.2–55.1°N) and Spain (at 41.5°N). From the 75th percentile and upwards, Finland had higher values than Germany. As an example, using the Swedish cohort as a comparator, the median 25(OH)D concentration was 3.03, 3.28, 5.41, 6.54 and 9.28 ng/ml lower in the German, Finnish, Italian, Scottish and Spanish cohort, respectively (P-value < 0.001 for all comparisons). The ordering of countries was highly consistent in subgroup analyses by sex, age, and decade and season of sampling. In conclusion, we confirmed the previous observation of a north-to-south gradient of 25(OH)D status in Europe, with higher percentile values among north-Europeans than south-Europeans.

Key words: Vitamin D: 25-hydroxyvitamin D: Latitude: Epidemiology: Europe: Population based

Vitamin D is a nutrient that has spurred substantial scientific debate over the last 30 years, mostly due to its role in musculoskeletal health(1). In addition, multiple studies have reported on an association between vitamin D status and risk of cancer, cardiac disease, stroke and diabetes (as reviewed by Mondul et al.(2), Rai et al.(3), Zhou et al.(4) and Lips et al.(5), respectively) as well as with...
overall mortality (as reviewed by Heath et al.\textsuperscript{(6)}) It is, however, unclear whether these are causal associations, given that randomised clinical trials and other controlled studies have yielded mostly null results\textsuperscript{7–10}. Recently, it was also hypothesised that vitamin D status might affect the severity of COVID-19\textsuperscript{11}.

Vitamin D status is defined by the total serum or plasma 25-hydroxyvitamin D (25(OH)D) concentration, of which the two major forms – with equal biological importance – are D\textsubscript{2} (ingested via plant-based or fortified foods) and D\textsubscript{3} (synthesised in human skin and/or ingested via animal-based or fortified foods)\textsuperscript{12}. The most important determinant of 25(OH)D status is thought to be sunlight, which initiates the cutaneous synthesis of 25(OH)D\textsuperscript{13}. North-Europeans have, therefore, often been viewed as more at risk for vitamin D insufficiency than other Europeans, mainly because the cutaneous synthesis of 25(OH)D is virtually undetectable from October to March at geographical latitudes above 50°N\textsuperscript{14}. However, in several European multicentre studies (n 824 to 55 844 participants) with harmonised (i.e. analysed in the same lab and with the same assay method) or standardised (i.e. using a Vitamin D Standardisation Program protocol\textsuperscript{15}) data on 25(OH)D, there has been a positive association between geographical latitude and 25(OH)D status\textsuperscript{16–23}; that is, the opposite of what is naively expected if sunlight is the main determinant of 25(OH)D. The reasons for this are unclear, but it has been suggested that between-country differences in diet (including food-fortification policies) and vitamin D supplement use are contributing factors\textsuperscript{24}.

Using harmonised data on 25(OH)D from more than 80 000 participants in the Biomarkers for Cardiovascular Risk Assessment in Europe (BiomarCaRE) project, we conducted the largest study to date on the association between geographical latitude and 25(OH)D status in Europe.

**Subjects and methods**

**Study population**

The present study is based on data from the BiomarCaRE project (www.biomarcare.eu) – details of which have been published elsewhere\textsuperscript{24} – which, in turn, is based on the Monitoring of Trends and Determinants in Cardiovascular Disease (MONICA) Risk, Genetics, Archiving, and Monograph (MORGAM) project\textsuperscript{25,26}. The MORGAM/BiomarCaRE Data Centre in Helsinki, Finland, harmonises and stores individual data from a large number of population-based European cohorts, and the BiomarCaRE laboratory (previously in Mainz), Germany, analyses and stores blood samples from several hundred thousand cohort participants.

A total of eight population-based cohorts (including 81 084 participants, of whom 3682 were examined more than once) from six European countries (Sweden, Finland, Scotland, Germany, Italy and Spain) had blood samples sent to the BiomarCaRE laboratory for 25(OH)D measurement and were included in the present study (Online Resource 1). The individual cohorts were: (1) MONICA Northern Sweden (Sweden; examination period 1986, 1990, 1994, 1999 (which also included re-examinations of the surveys in 1986–1994), 2004, 2009 and 2014); (2) FINRISK 1997 (Finland; examination period 1997); (3) Scottish Heart Health Extended Cohort (SHHEC) (Scotland; examination period 1984–1987, 1989, 1992 and 1995); (4) MONICA/Cooperative Health Research in the Region of Augsburg (KORA) (Germany; examination period 1994–1995 and 1999–2001); (5) MONICA Brianza (Italy; examination period 1986, 1990 and 1993); (6) Malattie Aterosclerotiche Istituto Superiore di Sanità (Italy; examination period 1993–1996); (7) Moli-sani (Italy; examination period 2005–2010) and (8) MONICA-Catalonia (Spain; examination period 1986–1988 and 1990–1992). Most cohorts examined participants throughout the calendar year (except for the Swedish and Finnish cohort, which examined participants almost exclusively in January to April) and almost all participants were assessed by serum samples (except for 4.4 % in the Swedish cohort, for whom only plasma samples were available). Each cohort was deemed representative of the population of interest (with participation rates ranging from 60 to 81 %). Further details of the cohorts are presented in Online Resource 2, with their approximate geographical location shown in Fig. 1.

**Ethical approval**

This study was conducted according to the guidelines laid down in the Declaration of Helsinki, and all procedures involving human subjects were approved by relevant local ethical review boards. Written informed consent was obtained from all participants. The recommendations of the Strengthening the Reporting of Observational Studies in Epidemiology initiative were followed whenever applicable\textsuperscript{27}.
Assessment of geographical latitude and other variables

Data on participant (i.e. sex, age and date of blood sampling) and blood sample characteristics (i.e. type of sampling material (serum or plasma) and date of analysis of 25(OH)D) were obtained from the MORGAM/BiomarCaRE Data Centre in Helsinki, Finland. Data on geographical latitude were based on the location of the largest city in each cohort’s recruitment area and retrieved from Google Maps (www.google.com/maps), except for in the SHHEC where district-level data on geographical latitude were available. For cohorts that had recruited participants over a large geographical area (i.e. MONICA Northern Sweden, FINRISK 1997 and SHHEC), the participants were classified into subcohorts according to the recruitment area or district area. The estimated geographical latitudes for the included cohorts are presented in detail in Online Resource 3. In brief, along a north-to-south axis, the following geographical latitudes were applied for each country: Sweden (65.6–63.8°N), Finland (65.0–60.2°N), Scotland (58.2–55.1°N), Germany (48.4–N), Italy (45.6–41.5°N) and Spain (41.5–N).

Assessment of 25-hydroxyvitamin D status

Serum or plasma analyses of 25(OH)D were conducted between 2009 and 2018 at the BiomarCaRE laboratory in Germany (located in Mainz up until 2012, thereafter in Hamburg) using a 1-step immunoassay on the Abbott ARCHITECT i2000 (Abbott Diagnostics)28. Previous research has shown that serum and plasma measurements of 25(OH)D are highly similar29. The cohort-specific years of analysis and intra-assay and inter-assay coefficients of variation are shown in Online Resource 4. No evidence of laboratory drift was observed during the study period (data not shown).

In a subgroup of the MONICA Northern Sweden cohort (n = 1522), the 25(OH)D status estimated from the Abbott ARCHITECT has been compared with that estimated from a HPLC-MS/MS (traceable to the National Institute of Standards and Technology’s Standard Reference Material 972)30,31, which is considered a more accurate method for 25(OH)D analyses32. Although the measurement methods had a good correlation in terms of rank (Spearman’s coefficient (r) = 0.82–0.91, irrespective of sex and age group), the 25(OH)D concentrations were on average 8–40 ng/ml lower when measured with the Abbott ARCHITECT.

Statistical analysis

A total of 81 084 participants and 84 766 blood samples were included for analysis. Data on 25(OH)D status were missing for 38 382 blood samples (4.5%, ranging from 1.0% in the Swedish cohort to 11.3% in the Scottish cohort). The main reasons for missing data were too small blood sample volumes (for the Scottish, German, Italian and Spanish cohorts) and technical issues during the laboratory procedure (for the Swedish and Finnish cohort). (See Online Resource 4 for cohort-specific percentages of missing data and reasons for missing data.) Missing data were handled using multiple imputation by chained equations (10 data sets were created and combined using Rubin’s rule33) in which sex, age, calendar year of sampling, calendar week of sampling, type of sampling material and cohort were included as regular variables. There was no evidence of violation of the missing at random assumption (data not shown). In a sensitivity analysis, we repeated the analyses using complete case data.

To study the exposure-outcome association in detail, we used quantile regression models and calculated percentile values (1st–99th) of 25(OH)D status according to country (ordered by decreasing geographical latitude: Sweden (comparator), Finland, Scotland, Germany, Italy and Spain) and geographical latitude (continuous, °N). Geographical latitude was modelled as a continuous variable assuming linearity (i.e. a constant change in 25(OH)D concentration for each unit of change in geographical latitude). To relax this assumption, we used 4-knot restricted cubic splines in a continuous analysis (knots at 65.0, 55.8, 48.4 and 41.6°N)34 and also performed a separate categorical analysis (using the northernmost sub-cohort (at 65.6°N) as comparator). A test for non-linearity in the restricted cubic spline model was conducted by testing the coefficients of the second and third spline transformation jointly equal to zero. In a sensitivity analysis, we repeated the analyses using mean regression models.

Multivariable quantile regression models were adjusted for sex, age (continuous, years), decade of sampling (1980s, 1990s, 2000s), calendar week of sampling (continuous, calendar weeks) and time from sampling to analysis (continuous, years). Since there was evidence of non-linear associations between 25(OH)D status and age (inverse J curve), calendar week of sampling (seasonal curve, as shown in Online Resource 5) and time from sampling to analysis (right-tilted L curve), we modelled these covariates using 4-knot restricted cubic splines (knots at the 5th, 35th, 65th and 95th percentile). Varying the number of knots (to 3 or 5 knots) had negligible influence on the results (data not shown).

Separate quantile regression models by (1) sex, (2) age (<51 median, >51 years), (3) decade of sampling (1980s, 1990s, 2000s) and (4) season of sampling (winter (December to February), spring (March to May), summer (June to August), fall (September to November)) were performed as subgroup analyses. Since a proportion of the Swedish cohort had been examined more than once (treated as independent observations in the main analysis; n = 5682) and/or with plasma instead of serum (n = 687), we also performed a sensitivity analysis by restricting the quantile regression model to first-time serum blood samples (n = 80 397).

Statistical significance was set at a two-sided P-value less than 0.05. Analyses were performed using Stata version 14 (StataCorp LP).

Results

A total of 81 084 participants (48.9% men; median age 50.8 years), who contributed with 84 766 blood samples during the 1980s (21.8%), 1990s (39.5%) and 2000s (38.8%), were included for analysis. Forty point two percentage were from Italy (n = 32 572), 18.4% from Scotland (n = 14 902), 14.8% from Sweden (n = 11 973, of whom 3682 had been examined more than once), 10.4% from Germany (n = 8 393), 9.9% from Finland

https://doi.org/10.1017/S0007114521005080 Published online by Cambridge University Press
Participant characteristics

<table>
<thead>
<tr>
<th>Country (ordered by decreasing geographical latitude)</th>
<th>Sweden</th>
<th>Finland</th>
<th>Scotland</th>
<th>Germany</th>
<th>Italy*</th>
<th>Spain</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of participants</td>
<td>11 973</td>
<td>8002</td>
<td>14 902</td>
<td>8393</td>
<td>32 572</td>
<td>5242</td>
</tr>
</tbody>
</table>

**Participant characteristics**

<table>
<thead>
<tr>
<th>Age (years)</th>
<th>51.2</th>
<th>48.4</th>
<th>49.8</th>
<th>50.2</th>
<th>53.1</th>
<th>45.7</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male sex</td>
<td>49.1</td>
<td>50.0</td>
<td>50.2</td>
<td>49.7</td>
<td>46.8</td>
<td>54.3</td>
</tr>
<tr>
<td>Decade of sampling</td>
<td>1980s</td>
<td>1990s</td>
<td>2000s</td>
<td>1980s</td>
<td>1990s</td>
<td>2000s</td>
</tr>
<tr>
<td>Winter (December to February)</td>
<td>10.2</td>
<td>7.9</td>
<td>31.9</td>
<td>31.9</td>
<td>27.6</td>
<td>23.5</td>
</tr>
<tr>
<td>Spring (March to May)</td>
<td>47.1</td>
<td>55.5</td>
<td>44.4</td>
<td>33.3</td>
<td>27.6</td>
<td>28.2</td>
</tr>
<tr>
<td>Summer (June to August)</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>8.6</td>
<td>19.8</td>
<td>18.1</td>
</tr>
<tr>
<td>Fall (September to November)</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>28.2</td>
<td>28.6</td>
<td>30.3</td>
</tr>
</tbody>
</table>

**Season of sampling**

<table>
<thead>
<tr>
<th>Type of sampling material</th>
<th>Serum</th>
<th>Plasma</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median</td>
<td>18.3</td>
<td>4.4</td>
</tr>
<tr>
<td>Range</td>
<td>15.9</td>
<td>–</td>
</tr>
<tr>
<td>Median age, 15 years</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

The Italian study population was recruited from three separate cohorts, for which details are given in Online Resource 6.

† Based on the total number of observations in each cohort (3682 participants in the Swedish cohort were examined more than once, leading to a total of 15 655 observations).

‡ Three participants in the Swedish cohort and one participant in the Finnish cohort were sampled in summer or fall.

The median 25(OH)D concentration was 16.4 ng/ml in the entire study population, 15.5 ng/ml in the female population and 17.3 ng/ml in the male population. As expected, there was a strong seasonal variation of 25(OH)D status (Fig. 2). In cohorts that had sampled participants throughout the calendar year, the highest and lowest median concentrations were observed in August to September and February to March, respectively, with an absolute (relative) peak-to-minimum variation of 10.7 ng/ml (96%) in Scotland, 14.7 ng/ml (110%) in Germany, 13.9 ng/ml (110%) in Italy and 11.6 ng/ml (122%) in Spain. The difference in 25(OH)D status according to the decade of sampling is presented in Online Resource 7. There were indications of higher 25(OH)D concentrations over time, with an absolute (relative) 2000s-to-1990s variation of 1.4 ng/ml (10%) during winter, 2.0 ng/ml (16%) during spring, 3.1 ng/ml (17%) during summer and 5.4 ng/ml (31%) during fall.

Unadjusted percentile values of 25(OH)D status by country are shown in Fig. 3. In the multivariable model, the ordering of countries by 25(OH)D status (from highest to lowest) was as follows up until the median percentile: Sweden (at 65°–63°S, Germany (at 48°N), Finland (at 65°–60°2’N, Italy (at 45°6–41°5’N, Scotland (at 58°2–55°1’N) and Spain (at 41°5’N (Table 2). From the 75th percentile and upwards, the Finnish cohort had higher values than the German cohort. As an example, using the Swedish cohort as comparator, the median (25th, 75th percentile) 25(OH)D concentration was 3.03 (2.36, 3.75) ng/ml lower in the German cohort, 3.28 (2.96, 3.48) ng/ml lower in the Finnish cohort, 5.41 (4.61, 6.17) ng/ml lower in the Italian cohort, 6.54 (5.27, 7.49) ng/ml lower in the Scottish cohort and 9.28 (7.65, 10.59) ng/ml lower in the Spanish cohort (P-value < 0.001 for all comparisons). The ordering of countries was highly consistent, although with some between-country differences in the magnitude of the exposure-outcome association, in subgroup analyses by sex, age, and decade and season of sampling (Table 3).

Likewise, the results were similar in the sensitivity analysis restricted to first-time serum blood samples (median difference (ng/ml) compared with Sweden: Germany −2.73, Finland −2.32, Italy −5.16, Scotland −6.12 and Spain −9.23; P-value < 0.001 for all comparisons) and in the sensitivity analysis based...
on the complete case data (Online Resource 8). The interpretation of the results did not change in the sensitivity analysis using mean regression (data not shown).

In the analysis of geographical latitude as a continuous variable, there was a positive association between geographical latitude and 25(OH)D status (median increase of 0.23 ng/ml for each 1-unit increase in geographical latitude (95 % CI 0.22, 0.24; P-value < 0.001)). However, as shown in Fig. 4, this linear dose–response model captured the shape of the exposure–outcome association very poorly compared with the restricted cubic spline model (P-value < 0.001 for non-linearity) and, especially, the categorical model. In countries with multiple recruitment areas, the within-country median difference in 25(OH)D concentration ranged from 0.35 ng/ml in Sweden to 2.81 ng/ml in Finland (based on the categorical exposure model).

**Discussion**

In this cross-sectional study, which included more than 80 000 participants from six European countries, we observed a north-to-south gradient of 25(OH)D status (although not linear in its shape), with higher percentile values in the northernmost countries (i.e. Sweden and Finland) compared with the southernmost countries (i.e. Spain and Italy). These findings were highly consistent in subgroup analyses by sex, age, and decade and season of sampling.

Several other studies with harmonised or standardised data on 25(OH)D have reported on a north-to-south gradient in Europe(16–23). In the EURONUT-SENECA study (n=824), men and women from Norway and Denmark had higher mean concentrations of 25(OH)D than their counterparts in Spain and Italy(16). Similar findings were observed in three randomised clinical trials of postmenopausal women (n=997–3195), where the mean concentrations of 25(OH)D were higher in northern Europe than in southern Europe(17–19). Deleskog et al. also reported on a positive association between geographical latitude and 25(OH)D status in a cohort of 3430 European men and women(20). In the ODIN project, which combined and standardised 25(OH)D data from eighteen European studies (n=55 844), the mean concentrations of 25(OH)D were higher in Norway and Iceland – but slightly lower in Finland – compared with Greece(21). Likewise, the mean concentrations of 25(OH)D were higher in Norwegian participants than in south-European participants in the European Eye study (n=4955)(22). Finally, in the European Prospective Investigation into Cancer and Nutrition-Interact case-cohort study (n=22 651), the authors observed a positive association between geographical latitude and 25(OH)D status(23).
Sunlight is an important determinant of 25(OH)D status, as exemplified by the strong seasonal variation in our data (the median concentration in the pooled population was 9.8 ng/ml lower in March than in August and September). However, based on the available literature of a north-to-south gradient, it is questionable if sunlight should be viewed as the most important determinant of 25(OH)D status in today's society(13), at least from a European perspective. In analogy, it may not be correct to view north-European populations as more at risk for vitamin D insufficiency than other European populations, despite the fact that the cutaneous synthesis of 25(OH)D is virtually undetectable during winter at geographical latitudes above 50°N(14).

Other factors that have a large influence on 25(OH)D status are the consumption of vitamin D-rich food items (e.g. fatty fish and shellfish) and vitamin D-fortified food items (e.g. milk and margarine) as well as the use of vitamin D-containing supplements(13). In the European Prospective Investigation into Cancer and Nutrition calibration study, which used a standardised FFQ and was based on data from 1995 to 2000 (n 36 034), it was observed that north-Europeans had a higher food intake of vitamin D than south-Europeans(15). The highest intakes were seen in the Swedish participants, most likely due to Sweden's long tradition of voluntary – and since 2007 mandatory – vitamin D fortification of milk, margarine and cooking fats(16). Interestingly enough, given that the Swedish cohort already had the highest 25(OH)D concentrations in our data, the vitamin D food-fortification policy in Sweden was expanded in 2018, so that it now includes more food items and dictates a higher quantity of vitamin D in each food item (Swedish National Food Agency, personal communication, 2019). At the time when the Finnish cohort was examined (1997), the Finnish legislation only allowed for voluntary vitamin D fortification of certain milk and margarine products by permission (Finnish Food Authority, personal communication, 2020). Since then, the Finnish Food Authority has started to recommend vitamin D fortification of all milk and margarine products, to which most companies have complied and that has led to increased 25(OH)D concentrations in the Finnish population(17). In the other countries that were included in our study, vitamin D-fortified products are commercially available, but its consumption is not specifically advised and there are no mandatory food-fortification policies (with the exception of margarine products in Scotland)(18). With respect to supplement use, it was observed in the previously mentioned European Prospective Investigation into Cancer and Nutrition calibration study that Swedish participants used supplements four to five times as often as Italian and Spanish participants(19). The Swedish participants were also more likely to use supplements that contained vitamin D. A potential
Table 2. Differences in 25(OH)D status in the study population (n 81 084, including 84 766 observations) by country and based on multiple imputed data sets (n 10)

<table>
<thead>
<tr>
<th>Country (ordered by decreasing geographical latitude)</th>
<th>25(OH)D status (ng/ml)</th>
<th>Percentile difference*</th>
<th>95% CI</th>
<th>Percentile difference*</th>
<th>95% CI</th>
<th>Percentile difference*</th>
<th>95% CI</th>
<th>Percentile difference*</th>
<th>95% CI</th>
<th>Percentile difference*</th>
<th>95% CI</th>
<th>Percentile difference*</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sweden</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Percentile 5%</td>
<td>-2.17</td>
<td>-2.50, -1.84</td>
<td>4.15</td>
<td>-4.46, -3.84</td>
<td>-1.33</td>
<td>-1.62, -1.04</td>
<td>-1.33</td>
<td>-1.62, -1.04</td>
<td>-1.33</td>
<td>-1.62, -1.04</td>
<td>-1.33</td>
<td>-1.62, -1.04</td>
<td>-1.33</td>
</tr>
<tr>
<td>Percentile 10%</td>
<td>-2.46</td>
<td>-2.77, -2.14</td>
<td>6.39</td>
<td>-4.35, -4.01</td>
<td>-1.43</td>
<td>-1.72, -1.14</td>
<td>-1.43</td>
<td>-1.72, -1.14</td>
<td>-1.43</td>
<td>-1.72, -1.14</td>
<td>-1.43</td>
<td>-1.72, -1.14</td>
<td>-1.43</td>
</tr>
<tr>
<td>Percentile 50%</td>
<td>-3.28</td>
<td>-3.65, -3.19</td>
<td>11.68</td>
<td>-6.86, -6.23</td>
<td>-3.03</td>
<td>-3.34, -2.73</td>
<td>-3.03</td>
<td>-3.34, -2.73</td>
<td>-3.03</td>
<td>-3.34, -2.73</td>
<td>-3.03</td>
<td>-3.34, -2.73</td>
<td>-3.03</td>
</tr>
<tr>
<td>Percentile 75%</td>
<td>-3.48</td>
<td>-3.95, -3.00</td>
<td>14.17</td>
<td>-7.87, -7.11</td>
<td>-3.75</td>
<td>-4.13, -3.36</td>
<td>-3.75</td>
<td>-4.13, -3.36</td>
<td>-3.75</td>
<td>-4.13, -3.36</td>
<td>-3.75</td>
<td>-4.13, -3.36</td>
<td>-3.75</td>
</tr>
<tr>
<td>Percentile 95%</td>
<td>-4.21</td>
<td>-5.21, -3.22</td>
<td>20.47</td>
<td>-9.50, -7.68</td>
<td>-4.69</td>
<td>-5.57, -3.81</td>
<td>-4.69</td>
<td>-5.57, -3.81</td>
<td>-4.69</td>
<td>-5.57, -3.81</td>
<td>-4.69</td>
<td>-5.57, -3.81</td>
<td>-4.69</td>
</tr>
</tbody>
</table>

25(OH)D, 25-hydroxyvitamin D; Comp., comparator.

* Estimated from quantile regression models adjusted for sex, age (continuous using 4-knot restricted cubic splines (4-RCS), years), calendar week of sampling (continuous using 4-RCS, calendar weeks), decade of sampling (1980s, 1990s, 2000s) and time from sampling to analysis (continuous using 4-RCS, years).
Table 3. Subgroup analyses of differences in 25(OH)D status in the study population (n 81 084, including 84 766 observations) by country and based on multiple imputed data sets (n 10)

<table>
<thead>
<tr>
<th>Country (ordered by decreasing geographical latitude)</th>
<th>Sweden</th>
<th>Finland</th>
<th>Scotland</th>
<th>Germany</th>
<th>Italy</th>
<th>Spain</th>
</tr>
</thead>
<tbody>
<tr>
<td>25(OH)D status (ng/ml)</td>
<td>Median difference*</td>
<td>95 % CI</td>
<td>Median difference*</td>
<td>95 % CI</td>
<td>Median difference*</td>
<td>95 % CI</td>
</tr>
<tr>
<td>By sex</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>By median age</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;51 years</td>
<td>-3.5</td>
<td>-4.02, -3.08</td>
<td>-5.77</td>
<td>-6.19, -5.36</td>
<td>-1.59</td>
<td>-1.99, -1.18</td>
</tr>
<tr>
<td>≥51 years</td>
<td>-1.94</td>
<td>-2.44, -1.43</td>
<td>-6.80</td>
<td>-7.22, -6.38</td>
<td>-4.38</td>
<td>-4.75, -4.01</td>
</tr>
<tr>
<td>By decade of sampling</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1990s</td>
<td>-5.44</td>
<td>-5.70, -5.19</td>
<td>-7.05</td>
<td>-7.45, -6.64</td>
<td>-5.19</td>
<td>-5.54, -4.85</td>
</tr>
<tr>
<td>2000s</td>
<td>-2.57</td>
<td>-2.96, -2.18</td>
<td>-3.92</td>
<td>-4.20, -3.64</td>
<td>-2.57</td>
<td>-2.96, -2.18</td>
</tr>
<tr>
<td>By season of sampling†‡</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Winter</td>
<td>7.77</td>
<td>7.20, 8.35</td>
<td>2.77</td>
<td>1.89, 3.65</td>
<td>3.67</td>
<td>3.09, 4.25</td>
</tr>
<tr>
<td>Spring</td>
<td>4.95</td>
<td>4.58, 5.32</td>
<td>2.91</td>
<td>2.33, 3.50</td>
<td>2.89</td>
<td>2.38, 3.40</td>
</tr>
<tr>
<td>Summer</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>5.18</td>
<td>3.65, 6.72</td>
</tr>
<tr>
<td>Fall</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>6.73</td>
<td>5.91, 7.56</td>
</tr>
</tbody>
</table>

25(OH)D, 25-hydroxyvitamin D; Comp., comparator.

* Estimated from quantile regression models adjusted for sex, age (continuous using 4-knot restricted cubic splines (4-RCS), years), calendar week of sampling (continuous using 4-RCS, calendar weeks), decade of sampling (1980s, 1990s, 2000s) and time from sampling to analysis (continuous using 4-RCS, years).
† Only three participants in the Swedish cohort and one participant in the Finnish cohort were sampled in summer or fall; therefore, to facilitate between-country comparisons across all subgroups, Scotland was used as the comparator group.
‡ Adjusted for the 3 months in each season of sampling (as a categorical variable).
1.0 to 11.3%). In cohorts with more than 3% missing data, the main reason for missingness was that the blood sample volumes were too small due to previous analyses at the BiomarCaRE laboratory. However, bias by missing data should have been kept to a minimum with the use of multiple imputation techniques (47). Fifthly, we had no data on – and could not adjust the analyses for – food and beverage consumption or use of vitamin D supplements. Sixthly, even though all of the included studies were population based in design, we cannot with certainty say that our findings are generalisable to populations outside of the recruitment areas or to the current point in time (especially since the Swedish and Finnish food-fortification policies have changed in recent years). A final limitation was that the 25(OH)D status was estimated with a 1-step immunoassay (Abbott ARCHITECT) and not a HPLC-MS/MS calibrated to a standard reference material (32). Our research group has previously validated the Abbott ARCHITECT against a HPLC-MS/MS (traceable to the National Institute of Standards and Technology’s Standard Reference Material 972) in a subgroup of the MONICA Northern Sweden cohort (30,31), and we observed a good correlation (in terms of rank, $r = 0.82-0.91$) but a general underestimation (on average 8-4 ng/ml) of 25(OH)D concentrations. As such, the absolute percentile values in our study should be interpreted with caution and not used for the classification of vitamin D deficiency (12) (to do so, a Vitamin D Standardisation Program protocol had been required (15)). However, due to the harmonised measurement, there is no reason to suspect a substantial variability in the underestimation of 25(OH)D status by country or cohort, meaning that the relative differences in percentile values should be valid.

In conclusion, in the largest study to date on the association between geographical latitude and 25(OH)D status in Europe, we confirmed the previous observation of a north-to-south gradient, with higher percentile values among north-Europeans than south-Europeans. These findings indicate that other factors are as, if not more, important as sunlight for 25(OH)D status in today’s European society. Future studies are needed to understand the underlying reasons for a north-to-south gradient of 25(OH)D status in Europe.

Acknowledgements

The BiomarCaRE laboratory in Hamburg (previously in Mainz), Germany, is directed by S. B. and headed by T. Z., whose team carried out the 25(OH)D measurements. The MORGAM/BiomarCaRE Data Centre in Helsinki, Finland, is headed by K. K., whose team handled and harmonised the data between the included cohorts and the BiomarCaRE laboratory.

The BiomarCaRE project was funded by the European Union (EU) Seventh Framework Programme (FP7, 2007–2013) under grant agreement no. HEALTH-F2-2011-278913. The MORGAM Data Centre has also been sustained by recent funding from the EU FP7 project CHANGES (no. HEALTH-F3-2010-242244) and the EU Horizon 2020 projects euCanSHare (no. 825903) and AFFECT-EU (no. 847770). Parts of the 25(OH)D measurements were funded by the Medical Research Council London (G0601463, no. 80983: Biomarkers in the MORGAM Populations). The KORA study was initiated and financed by the Helmholtz Zentrum München and also supported within.
the Munich Center of Health Sciences, Ludwig-Maximilians-Universität, as part of the LMUinnovativ. The MONICA-Catalonia study was financed by the Institute of Health Studies, Catalan Department of Health. The SHHEC study was financed by the Scottish Health Department Chief Scientist Office, the British Heart Foundation and the FP Fleming Trust. V. O., M. E. and S. S. O. were supported by grants from: (1) the County Councils of Norrbotten and Västerbotten, (2) the Piteå Alvdals Hospital Foundation, (3) the Joint Committee of County Councils in northern Sweden and (4) Umeå University, Umeå, Sweden. V. S. was supported by grants from the Finnish Foundation for Cardiovascular Research.

The authors’ responsibilities were as follows—V. S., S. S. O., M. E., H. T. P., B. T., M. M. F., L. I., L. P., C. D. and S. S. A. acquired the original data; V. O. and S. S. O. acquired the derived data; J. R. prepared the derived data and advised on its use and interpretation; V. O. performed the statistical analyses; V. O., M. E. and S. S. O. interpreted the results and drafted the manuscript; and V. O. and S. S. O. primary responsible for the final content. All authors reviewed and revised the manuscript, approved the final version of the manuscript and participated in the study design.

Abbott Diagnostics provided test reagents for the 25(OH)D measurements within the frame of the BiomarCaRE project. Abbott Diagnostics had no role in the study design, data collection, blood sample and data analysis, decision to publish or preparation of the manuscript. S. S. O. has received personal fees from Actelion Pharmaceuticals Ltd (outside of the submitted work). V. S. has received honoraria from Novo Nordisk and Sanofi for consulting and has an ongoing research collaboration with Bayer Ltd (all outside of the submitted work). S. B. has received research funding from Abbott Diagnostics, Bayer, SIEMENS, Singulex and Thermo Fisher. He has also received honoraria for lectures from Abbott, Abbott Diagnostics, AstraZeneca, Bayer, AMGEN, Medtronic, Pfizer, Roche, SIEMENS Diagnostics, SIEMENS and Thermo Fisher as well as for being a member of advisory boards and for consulting for Bayer, Novartis and Thermo Fisher. The other authors have no conflicts of interest to declare.

Supplementary material

For supplementary material referred to in this article, please visit https://doi.org/10.1017/S0007114521005080

References


https://doi.org/10.1017/S0007114521005080


